Minervax is a biotechnology company developing a novel vaccine against Group B Streptococcus.
Minervax has raised $57.4M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in October 2023.
Minervax's investors include European Investment Bank, OrbiMed, EQT Life Sciences, Wellington Partners, Novo Holdings.
Minervax is headquartered in Hellerup, Denmark.
Minervax is a biotechnology company developing a novel vaccine against Group B Streptococcus.
Minervax is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Minervax — Funding & Investors." VCBacked, October 11, 2023, https://www.vcbacked.co/company/minervax. Accessed August 8, 2026.
VCBacked. (2023). Minervax — Funding & Investors. Retrieved August 8, 2026, from https://www.vcbacked.co/company/minervax
{{cite web |title=Minervax — Funding & Investors |url=https://www.vcbacked.co/company/minervax |website=VCBacked |access-date=August 8, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated